Diagnostic value of tumour marker regression models in stage 1 marker-positive testicular cancer

Urologia Internationalis

Volumn 73, Issue 4, 2004, Pages 329-336

  May, Matthias ^a,c   Helke, Christian ^a   Nitzke, Thomas ^b   Seehafer, Matthias ^a   Vogler, Horst ^b   Hoschke, Bernd ^a  

^a Carl Thiem Hospital   (Germany)

^b VIVANTES HOSPITAL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Half life periods; Predicting tumour stages; Testicular cancer; Tumour marker

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER STAGING; CHILD; CLEARANCE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; REGRESSION ANALYSIS; TESTIS CANCER;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CHILD; CHILD, PRESCHOOL; CHORIONIC GONADOTROPIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TESTICULAR NEOPLASMS;

EID: 10844283450     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081594     Document Type: Article

References (26)

1. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC: Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808-811.
2. Batzler WU, Bertz J, Eisinger B, Hentschel S, Husmann G, et al: Study Group Population-Related Cancer Index in Germany in Cooperation with the Robert Koch Institute. Cancer in Germany - Incidence and Trends, ed 3 (extended and updated), Saarbrücken 2002.
3. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Challier E, Lebret T, Cluzel P: Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience. Radiology 1998;207:799-808.
4. Federal Board of Physicians and Health Insurances: Guidelines of the Federal Board of Physicians and Health Insurances on criteria to assess the quality of the radiological diagnosis according to § 136 SGB V, edition of June 17, 1992, last modi. ed on December 17, 1996. Dtsch Ärztebl 1997; 94:C581-C588.
5. Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U: Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900-904.
6. deVere White R, Karian S, Hong WK, Olsson CA: Testis tumor markers: How accurate are they? J Urol 1981;125:661-663.
7. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG: Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994;44:548-552.
8. Foster R, Bihrle R: Current status of retroperitoneal lymph node dissection and testicular cancer: When to operate. Cancer Control 2002;9: 277-283.
9. Heidenreich A: Clinical stage I nonseminomatous testicular germ-cell tumors: Surgery or watchful waiting, still an issue? Curr Opin Urol 2002;12:427-430.
10. Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E: Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997;33:1038-1044.
11. Krug B, Heidenreich A, Dietlein M, Lackner K: The lymph node staging of malignant testicular germ-cell tumors (in German). Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 1999;171:87-94.
12. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 1982;128:708-711.
13. Lashley DB, Lowe BA: A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25:405-423.
14. Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP: Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 1998;16:261-268.
15. Lo RK, Johnson DE: A graphical method to analyze serum tumor marker decay in nonseminomatous testis tumors. J Urol 1984;131:896-898.
16. 18F]-2-fluoro-2-deoxy-D-glucose in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A 1998;37:609-620.
17. Niwakawa M, Tobisu K: The role of tumor markers in the treatment of germ cell tumor (in Japanese). Gan To Kagaku Ryoho 2001;28:1159-1165.
18. Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M: Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: Rationale for different risk-adapted treatment. Eur Urol 1998;33:562-566.
19. Pritchett TR, Skinner DG: Embryonal carcinoma with falsely positive elevation of serum α-fetoprotein after curative therapy: A case report. J Urol 1984;131:970-971.
20. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA: Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762-1768.
21. Scardino PT, Cox HD, Waldmann TA, Mcintire KR, Mittemeyer B, Javadpour N: The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol 1977;118:994-999.
22. See WA, Cohen MB, Hoxie LD: Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity. Cancer 1993;71:2048-2054.
23. Souchon R, Schmoll HJ, Krege S, German Testicular Cancer Study Group: Guidelines on Diagnostic and Therapy of Testicular Cancer on the Basis of Evidence-Based Medicine, ed 1. München, Zuckerschwerdt, 2002.
24. Steyerberg EW, Keizer HJ, Sleijfer DT, Fossa SD, Bajorin DF, Gerl A, de Wit R, Kirkels WJ, Koops HS, Habbema JD: Retroperitoneal metastases in testicular cancer: Role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology 2000;215:437-444.
25. Van der Gaast A, Hoekstra JW, Croles JJ, Splinter TA: Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma. J Urol 1991;145:829-831.
26. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, Von der Maase H: Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 2002;20:4448-4452.